Drugs / KDS2010
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07027072 | Aug 2025 → Jun 2027 expected | Alzheimer disease | NeuroBiogen Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07009171 | Jul 2025 → Jan 2027 expected | obesity disorder | NeuroBiogen Co., Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-11 | Scilex Pharmaceuticals, Inc. | Results Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor gcs-web.com ↗
KDS2010 pharmacokinetics, lack of food effect, safety and dose selection have been characterized in Single Ascending Dose and Multiple Ascending Dose Phase 1 clinical trials with 88 healthy young adults and elderly subjects, demonstrating favorable safety and tolerability and adequate pharmacokinetics for once-daily dosing. |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KDS2010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07009171 ↗ |
| Action | Inhibit | “KDS2010, a novel, reversible monoamine oxidase-B (MAO-B) inhibitor” NCT07009171 ↗ |
| Route | Oral | “KDS2010 will be administered orally once daily” NCT07009171 ↗ |